Reinhard Angermann - Publications

Real-world outcomes after switching to faricimab in previously treated neovascular age-related macular degeneration: longitudinal outcomes up to 24 months.

Journal: International journal of retina and vitreous

Published: April 03, 2026

Emmetropia Verifying Optical (EVO) formula in secondary scleral fixation using the Yamane technique: a retrospective comparison of intraocular lens power calculation formulas.

Journal: BMC ophthalmology

Published: November 16, 2025

Progerin mRNA Is Associated with Smoking and Signs of Increased Microvascular Damage in Patients with Diabetic Macular Edema.

Journal: International journal of molecular sciences

Published: December 27, 2024

Systemic counterregulatory response of angiopoietin-2 after intravitreal injections with faricimab for nAMD.

Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

Published: July 25, 2024

Faricimab maintains substance integrity and sterility after compounding and storage in two different polypropylene syringe types.

Journal: Eye (London, England)

Published: March 11, 2024

Long-term persistence with aflibercept therapy among treatment-naïve patients with exudative age-related macular degeneration in a universal health care system: a retrospective study.

Journal: BMC ophthalmology

Published: August 20, 2022

Retinal layer thinning as a biomarker of long-term disability progression in multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: June 02, 2022

The Impact of the COVID-19 Pandemic on the Quality of Care of Treatment-Naïve Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept.

Journal: Klinische Monatsblatter fur Augenheilkunde

Published: April 21, 2022

Efficiency benchmarks in the surgical management of primary rhegmatogenous retinal detachment: a monocentric register cohort study of operating room time metrics and influential factors.

Journal: BMJ open

Published: December 22, 2021

Intravitreal Aflibercept Therapy and Treatment Outcomes of Eyes with Neovascular Age-Related Macular Degeneration in a Real-Life Setting: A Five-Year Follow-Up Investigation.

Journal: Ophthalmology and therapy

Published: November 08, 2021

CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

Journal: Retina (Philadelphia, Pa.)

Published: November 03, 2021

Effects of Intravitreal Aflibercept on the Systemic Insulin-like Growth Factor-I and Vascular Endothelial Growth Factor-A in Patients with Diabetic Retinopathy and Age-Related Macular Degeneration.

Journal: Journal of ophthalmology

Published: August 31, 2021